We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently.In this article, we are going to take a look at where Nuvalent, Inc. (NASDAQ:NUVL) stands against the other feminist stocks. We previously covered 10 Mid-Cap Stocks Insiders Are Buying Recently.

Why should investors analyze insider trading activity? Insiders, or people in high positions within a company—such as executives and directors—can have crucial insights into the company’s strategic moves, plans, and initiatives. When, for example, a CEO invests their own capital in company stocks, it can indicate strong confidence in the company’s future results.

What does it mean when insiders are selling their shares? It doesn’t necessarily mean bad news for the stock. Sometimes, large shareholders just want to trim their holdings to more appropriate position sizes based on the risk/reward potential.

It is important to note that both insider selling and buying can be driven by various motives. Therefore, any insider trading activity should be analyzed within the broader context of the company’s fundamentals, industry trends, and overall market conditions. Many insider purchases don’t necessarily mean the company will be successful. That’s why due diligence before any investment is of the utmost importance. Investors should also take into account and carefully analyze underlying reasons for insider transactions. However, insider trading activity in combination with other relevant factors can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.

To identify the 10 mid-cap stocks insiders are selling recently, we considered only stocks with a market capitalization of between $2 billion and $10 billion. We first used Insider Monkey’s insider trading stock screener and looked for stocks with at least two insiders buying over the last two months.

With each stock we note the number of recent insider sales and the company’s current market capitalization. But why is it important to follow insider activity? Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here)

A physician standing in a lab, with vials of biopharmaceuticals in hand.

Story Continues

Nuvalent, Inc. (NASDAQ:NUVL)

Number of Insiders Selling: 8

Market Capitalization: $6.16B

Nuvalent is a clinical-stage biopharmaceutical company focused on therapies for cancer. Its robust pipeline includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Since it went public in July 2021, Nuvalent shares gained 363.29%.

Over the last two months, eight insiders, including President and CEO, CFO, CMO, and CSO, sold around $116.92 million worth of Nuvalent shares at an average price of $80.53. Nuvalent’s shares are now trading at $85.53, having gained 9.26% year-to-date. Over the past 12 months, the stock went up 2.36%.

Data from Stock Analysis shows that the average rating from 11 analysts is “Strong Buy,” and the 12-month stock price expectation is $112.36.

Even though Nuvalent is one of the 10 mid-cap stocks insiders are selling recently, at the same time it is the first of Joseph Edelman’s top 10 Long-Term Stock Picks. Edelman is a very respected investor recognized for his expertise in biotechnology and healthcare investing. He is the founder, CEO, and portfolio manager of Perceptive Advisors.

While some insiders reduced their positions within Nuvalent recently, some hedge funds, like Perceptive Advisors, Woodline Partners and Driehaus Capital grew their holding in the third quarter of 2024.

What makes Nuvalent an interesting investment is its innovative drug pipeline and focus on precision oncology. The company’s leading drug candidates target cancers driven by ROS1 and ALK gene alterations.

According to the company’s report for the quarter ended September 30, 2023, cash equivalents and marketable securities amounted to $1.2 billion, compared to $732.38 million at the end of 2023.

Overall NUVL ranks 7th on our list of the mid-cap stocks insiders are selling recently. While we acknowledge the potential of NUVL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Nowand Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.

View Comments